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Abstract
 IMPORTANCE—Parkinson disease (PD) is a progressive neurodegenerative disease for which 
susceptibility is linked to genetic and environmental risk factors.
 OBJECTIVE—To identify genetic variants contributing to disease risk in familial PD.
 DESIGN, SETTING, AND PARTICIPANTS—A 2-stage study design that included a 
discovery cohort of families with PD and a replication cohort of familial probands was used. In the 
discovery cohort, rare exonic variants that segregated in multiple affected individuals in a family 
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and were predicted to be conserved or damaging were retained. Genes with retained variants were 
prioritized if expressed in the brain and located within PD-relevant pathways. Genes in which 
prioritized variants were observed in at least 4 families were selected as candidate genes for 
replication in the replication cohort. The setting was among individuals with familial PD enrolled 
from academic movement disorder specialty clinics across the United States. All participants had a 
family history of PD.
 MAIN OUTCOMES AND MEASURES—Identification of genes containing rare, likely 
deleterious, genetic variants in individuals with familial PD using a 2-stage exome sequencing 
study design.
 RESULTS—The 93 individuals from 32 families in the discovery cohort (49.5% [46 of 93] 
female) had a mean (SD) age at onset of 61.8 (10.0) years. The 49 individuals with familial PD in 
the replication cohort (32.6% [16 of 49] female) had a mean (SD) age at onset of 50.1 (15.7) 
years. Discovery cohort recruitment dates were 1999 to 2009, and replication cohort recruitment 
dates were 2003 to 2014. Data analysis dates were 2011 to 2015. Three genes containing a total of 
13 rare and potentially damaging variants were prioritized in the discovery cohort. Two of these 
genes (TNK2 and TNR) also had rare variants that were predicted to be damaging in the 
replication cohort. All 9 variants identified in the 2 replicated genes in 12 families across the 
discovery and replication cohorts were confirmed via Sanger sequencing.
 CONCLUSIONS AND RELEVANCE—TNK2 and TNR harbored rare, likely deleterious, 
variants in individuals having familial PD, with similar findings in an independent cohort. To our 
knowledge, these genes have not been previously associated with PD, although they have been 
linked to critical neuronal functions. Further studies are required to confirm a potential role for 
these genes in the pathogenesis of PD.
Parkinson disease (PD) is a progressive neurodegenerative disease for which susceptibility is 
linked to genetic and environmental risk factors. Linkage studies have previously identified 
rare mutations responsible for PD in large, multiplex families,1–5 and whole-exome 
sequencing (WES) has been used successfully in such pedigrees more recently.6,7 It is 
recognized that PD is genetically heterogeneous, and many additional genes remain to be 
discovered, particularly in families with strong disease aggregation. Most important, several 
genes initially identified in familial PD have subsequently been demonstrated to have 
substantial contributions to sporadic PD without known family history (eg, LRRK2 G2019S 
[OMIM 609007], GBA N307A [OMIM 606463], and the occurrence of rare and common 
variant alleles at SNCA [OMIM 163890]). Therefore, elucidation of rare alleles with strong 
effects on disease risk in families can have important implications for our understanding of 
the genetic architecture of PD in the general population.
Whole-exome sequencing yields more than 20 000 exonic single-nucleotide variants (SNVs) 
per individual,8 requiring a strategy to narrow the number of variants. In pedigrees 
characterized by potential autosomal dominant inheritance, filtering strategies based on 
segregation have facilitated identification of causal variants. However, this approach requires 
large, multigenerational pedigrees with available genetic samples and clinical 
characterization. By contrast, small to moderately sized families with PD are less 
informative for segregation analyses, leaving many variants after using bioinformatic filters 
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to predict damaging alleles. Even in well-defined cases of mendelian PD (with SNCA or 
LRRK2), there are instances in which not all affected family members carry the mutation 
(ie, intrafamilial heterogeneity).3,9,10 As recently suggested in amyotrophic lateral 
sclerosis,11 oligogenic inheritance (in which multiple rare alleles contribute to individual 
risk) may also have a role in PD susceptibility. Therefore, some of the successful analytic 
strategies developed for simple mendelian disorders may need to be adapted for continued 
successful gene discovery in complex genetic disorders such as PD.
To date, WES in PD has been reported in studies involving one or a few families6,7,12–15 or 
in candidate gene investigations.16 We applied an innovative 2-stage study designed to 
address some challenges that are inherent in gene discovery in common, complex disorders. 
The first stage used exomes from a discovery cohort of multiplex families with PD. Each 
family was examined for segregating candidate variants, allowing for intrafamilial 
heterogeneity. We then prioritized genes identified across multiple families, allowing for 
allelic heterogeneity. In the second stage, we analyzed the most promising genes in an 
independent replication cohort of sequenced probands with familial PD. We identified the 
subset of candidate genes containing rare, potentially functional variants that may contribute 
to disease risk (Figure 1).
 Methods
 Discovery Cohort Participants
The study protocol was approved by the Indiana University Institutional Review Board and 
by the ethics boards of all study sites. Families with at least 1 pair of living siblings 
diagnosed as having PD were evaluated by Parkinson Study Group movement disorder 
neurologists. Written informed consent was obtained from all participants. Validated 
checklists17,18 were used to assign clinical diagnosis of PD. Individuals classified as having 
verified PD met United Kingdom Parkinson’s Disease Brain Bank criteria,19 modified only 
to allow for positive family history. Individuals having no signs of a movement disorder 
were considered to have no evidence of PD. The remaining individuals were classified as 
having nonverified PD. These individuals had evidence of a movement disorder but failed to 
meet all inclusion criteria or met at least 1 exclusion criterion. All brain autopsies completed 
at the time of sequencing (n = 5) confirmed the diagnosis of PD. Peripheral blood was 
obtained from all individuals who provided written informed consent. Clinical evaluations or 
biospecimens from unaffected family members were not available as part of this study.
 Discovery Samples
Whole-exome sequencing and annotation of identified variants (eMethods in the 
Supplement) were performed in 32 families with the largest number of verified PD cases 
without another segregating neurological disorder and without a known causative PD 
mutation in LRRK2 or PARKIN (OMIM 602544). Among the 32 families, 90 individuals 
with verified PD underwent sequencing. An additional 3 individuals initially classified as 
having nonverified PD were also included as affected cases. Two had neuropathological 
confirmation of PD. The third met all clinical inclusion criteria (including onset after age 20 
years, bradykinesia, persistent asymmetry, and diagnosis by a movement disorders 
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neurologist) and had significant supporting criteria (including rigidity, postural instability, a 
resting tremor, disease progression, and a positive response to levodopa) but met the sole 
exclusion criterion of having concomitant Alzheimer disease and sensory deficits. Of the 32 
families (eFigures 1, 2, 3, and 4 in the Supplement), 6 had 2 cases sequenced, 23 had 3 cases 
sequenced, and 3 had 4 cases sequenced.
 Filtering
Variants were retained (Figure 1) if they (1) were predicted to be SNVs or insertions/
deletions (indels) in an exonic or splicing region based on 1 or more gene databases 
(eMethods in the Supplement), (2) had an allele frequency of less than 3% in European 
American populations in the annotated public and internal frequency databases, (3) were 
predicted to be damaging by at least 1 in silico protein functional and structural effect 
prediction program (eMethods in the Supplement) or were located in a highly conserved 
region, and (4) segregated with at least 2 PD cases in the same family. Genes were retained 
if they (1) were in a relevant Gene Ontology (GO) category,20,21 (2) were expressed in the 
brain, and (3) had retained variants that were observed in at least 2 cases in at least 4 
families.
 Replication Cohort and Variant Confirmation
The prioritized genes were examined in WES (eMethods in the Supplement) from a 
replication cohort of 49 unrelated individuals with familial PD. All individuals were 
diagnosed as having PD based on examination by movement disorders neurologists and 
reported at least 1 first-degree relative diagnosed as having PD. The study was approved by 
the Baylor College of Medicine Institutional Review Board and written informed consent 
was obtained from all participants. Compared with the discovery pipeline, a more stringent 
allele frequency filter (<1% in European American populations from 1000 Genomes and 
ESP) was used.22,23 Potentially deleterious and highly conserved variants were identified 
using SIFT, PolyPhen-2, MutPred, and GERP24–27 Variants present in genes prioritized from 
the discovery analysis were extracted.
All variants in replicated genes identified in the discovery and replication cohorts were 
reviewed in the Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org) and 
were confirmed using targeted polymerase chain reaction and Sanger sequencing. Variants 
were annotated for Combined Annotation Dependent Depletion (CADD) (http://
cadd.gs.washington.edu),28 in which C-scores of at least 10 and at least 20 correspond to the 
10% and 1% most deleterious substitutions in the genome, respectively. Genes were 
annotated for residual variation intolerance score (RVIS) percentiles, in which lower 
percentiles correspond to genes that are most intolerant of functional mutations.29
 Simulation
Simulated WES data sets using ExAC allele frequencies were generated and interrogated 
with the identical discovery and replication filtering pipeline described above, except for the 
use of segregation within families (eMethods in the Supplement) because the ExAC database 
consists of unrelated individuals and therefore does not contain data regarding segregation. 
A simulation was performed with data sets from 150 000 randomly chosen SNVs to parallel 
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the number of variants identified in our families with PD, and a more conservative 
simulation was conducted with 250 000 SNVs to establish a range of P values.
 Results
 Discovery Cohort
Clinical characteristics of 93 individuals from the 32 families in the discovery cohort are 
summarized in Table 1. Pedigrees and sequencing quality control metrics are provided in 
eFigures 1, 2, 3, and 4 and the eMethods in the Supplement.
Application of the Genome Analysis Toolkit30 (https://www.broadinstitute.org/gatk/) quality 
filters resulted in 149 055 SNVs and 9378 indels across all samples (22 188–28 230 variants 
per sample) (Figure 1). Nonsynonymous SNVs or indels within an exon having an allele 
frequency of less than 3% were retained. After removing variants that were predicted to be 
benign by all 4 protein prediction programs (eMethods in the Supplement) and were not in a 
highly conserved region, approximately 10% of the original variants remained. We next 
considered each family independently and filtered based on segregation, requiring that 
candidate variants must be shared by at least 2 affected individuals, allowing for allelic 
heterogeneity within a family, as has been seen with other genes associated with PD.3,9,10 
Single-nucleotide variants identified in the filtered genes with GO annotation are listed in 
eTable 1 in the Supplement.
We performed an integrated analysis across our discovery sample to identify genes with 
damaging alleles in at least 4 families. Because many variants remained (eTable 1 in the 
Supplement), we further restricted the list of prioritized genes based on established gene 
expression in the brain and a priori participation in biologic categories strongly implicated in 
PD. This strategy identified 3 genes (TNK2 [OMIM 606994], TNR [OMIM 601995], and 
TOPORS [OMIM 609507]), each of which had filtered variants observed in both the Center 
for Inherited Disease Research and HudsonAlpha Institute for Biotechnology sets of 
families.
 Replication Cohort
Clinical characteristics of the 49 probands with familial PD in the replication cohort are 
summarized in Table 1. Sequencing metrics are described in the eMethods in the 
Supplement.
Rare variants predicted to be damaging in the 3 genes prioritized in the discovery analysis 
were extracted from the replication WES data. Two genes (TNK2 and TNR) that harbored 
variants of interest (Replication Cohort and Variant Confirmation subsection of the Methods 
section) in the discovery cohort were also found to have distinct variants of interest in the 
replication cohort (Table 2).
In total, the 2 genes were observed to harbor 9 distinct potentially functionally relevant 
variants (Table 3). All 9 variants were confirmed by targeted polymerase chain reaction and 
Sanger sequencing in all relevant samples (eTable 2 in the Supplement). Genic intolerance 
RVIS percentiles29 and CADD C-scores28 were computed to characterize the potential effect 
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of functional mutations at the gene level and variant level, respectively. The 2 genes had a 
mean (SD) RVIS of −0.63 (0.13) and a mean (SD) percentile of 17.2% (4.1%). The 
calculated RVIS percentiles reflect purifying selection or probable greater intolerance for 
mutations within the gene than most genes. For example, TNK2 has an RVIS of −0.72 and a 
percentile of 14.3%, placing it among the 14.3% most intolerant of genes. In contrast, genes 
known to cause autosomal dominant PD (ie, SNCA, LRRK2, and VPS35 [OMIM 601501]) 
have a mean (SD) RVIS of −0.65 (0.50) and a mean (SD) percentile of 21.5% (0.2%).
The mean (SD) CADD C-score for the 9 variants was 23.9 (6.4). All 9 variants are predicted 
to be within the 1% most deleterious variants in the genome, with the exceptions of the 
TNK2 pA977V variant and the TNR pT166A variant, both of which still fall within the 
predicted 10% most deleterious variants.
To estimate the significance of our findings, we examined many simulated discovery and 
replication data sets and determined the likelihood of similar observations by chance. After 
application of the filtering pipeline to the 10 000 data sets produced from 150 000 randomly 
chosen ExAC SNVs, one data set yielded 2 genes (P < .001), and 163 data sets yielded 1 
gene each (P = .02). To provide a more conservative estimate of statistical likelihood, 10 000 
data sets were then simulated from 250 000 randomly chosen ExAC SNVs. Of the 10 000 
data sets, 9 yielded 2 genes (P < .001), and 340 yielded 1 gene (P = .03) after applying the 
filtering pipeline.
 Discussion
Using WES in discovery and replication cohorts of individuals with familial PD, we 
detected 9 likely deleterious, rare exonic variants in 2 genes (TNK2 and TNR) that may have 
a role in PD susceptibility (Table 3). All variants were heterozygous, consistent with 
dominant inheritance and the pedigree structures (Figure 2), suggesting that the disease 
phenotype results from a gain-of-function, haploinsufficiency, or dominant-negative 
mechanism. The candidate variants identified may contribute to PD risk in 12 families from 
our study, including one family in which variants in both genes are cosegregating. To our 
knowledge, neither TNK2 nor TNR has previously been implicated in PD susceptibility 
from genetic investigation of large pedigrees or from genome-wide association studies in 
population cohorts.
TNK2 encodes for a nonreceptor tyrosine kinase (activated CDC42 kinase 1) that is 
important for cell growth, survival, and migration. Findings from some studies31–33 suggest 
that TNK2 is involved in synaptic function and plasticity, and the results of a recent study34 
propose that TNK2 mutations may cause autosomal recessive infantile-onset epilepsy. Other 
studies35,36 have established links between the TNK2 protein and the epidermal growth 
factor receptor (EGFR [OMIM 131550]). In the discovery and replication cohorts, 4 unique 
rare nonsynonymous TNK2 variants were identified. Of the 5 families in the discovery 
cohort that had 2 or more members who shared a candidate TNK2 variant, 2 families 
showed complete segregation (ie, all sequenced members of the family carried the variant of 
interest) (Figure 2). None of the family members of the probands from the replication cohort 
could be assessed for inheritance of variants of interest. One of the TNK2 variants identified 
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in this study (pV363A) is found in the EGFR inhibitor Mig-6 domain (IPR021619 and 
PF11555). Binding of Mig-6 to the kinase domain of EGFR inactivates the receptor, which 
suggests that this domain in the TNK2 protein may also be important for appropriate 
regulation of its function.
TNR, or tenascin R, encodes an extracellular matrix glycoprotein that is only found in the 
central nervous system.37 Tenascin R is thought to be involved in neurite growth, neural cell 
adhesion, and sodium channel functioning.38,39 Of the 6 unique variants prioritized in TNR, 
5 were found only in the discovery cohort as rare nonsynonymous variants. One variant 
(pR578X) was found solely in the replication cohort and results in addition of a stop site at 
position 578 of a 1358 amino acid protein. This variant, along with one other variant 
(pT592A), is found in the fibronectin type 3 domain (IPR003961) of the protein, which is 
important for cell surface binding.
Given the prevalence, late onset, and incomplete penetrance of PD, we expect that PD 
susceptibility alleles are likely observed at low frequencies within public databases. 
Therefore, we used a conservative 3% minor allele frequency filter in the discovery phase to 
retain these variants. In the replication phase, which uses familial samples but does not have 
the advantage of examining allele sharing within each family, we used a more stringent 1% 
minor allele frequency filter to gather additional evidence for the genes nominated from the 
discovery analysis. The final variants identified (Table 3) were not observed (n = 2) or were 
observed at low frequencies (n = 7) in the ExAC database. This finding is consistent with the 
expectation that causative alleles may still be observed within public databases, especially 
given that the ExAC database includes individuals as young as 18 years, at which age 
clinical manifestations of PD are unlikely.
Unlike previous studies6,7,13,40 focused on a single large pedigree or on extensive data sets 
of unrelated individuals, our blended approach leveraged a well-characterized set of 
moderately sized families and an additional set of unrelated familial probands. Also, a major 
advantage of this study is that both cohorts included only individuals with familial PD. 
Families with multiple affected members are more likely to be enriched for causative, 
moderately rare variants having a modest or large effect size.
Our experimental design contrasts with recent efforts that sequenced large pedigrees to 
identify variants with fully penetrant effects responsible for strictly mendelian PD. This 
category of variants appears to account for rare causes of PD,6,7,13 and heterogeneity has 
been observed even in these families.3,16,17 Our study design allows for detection of such 
mutations but also permits discovery of rare variants with intermediate penetrance such as 
LRRK2 G2019S41 and mutations in GBA (OMIM 606463).42 Because 10% to 20% of 
patients with PD report having at least 1 first-degree relative affected by PD,43–45 it is likely 
that variants of intermediate penetrance remain a major contributor to PD heritability. 
Experimental designs that allow for exploration of intrafamilial and interfamilial 
heterogeneity are particularly important for studying PD. To limit false-positive results that 
are inherent in a prioritization scheme that requires incomplete allelic segregation in 
families, we used a 2-stage study design to increase the likelihood that the candidate genes 
identified in this study are involved in the etiology of PD.
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One pedigree from our study (family C in Figure 2) illustrates possible intrafamilial 
heterogeneity involving cosegregation of variants in both TNK2 and TNR. All sequenced 
family members carry at least 1 of 2 variants (TNK2 pR877H and TNR pT592A). Individual 
4 is heterozygous for both variants and had a younger age at onset than his siblings (49 vs 64 
years), each of whom carries only a single variant in either gene. In other pedigrees (families 
P and AD in Figure 2), the cause of PD in individuals not carrying the identified variant may 
also be due to another unidentified gene or environmental insult. These pedigrees illustrate 
possible intrafamily oligogenic inheritance or phenocopies that would likely be missed by 
family-based sequencing study designs based on monogenic and completely penetrant 
inheritance models.
It is notable that the 2 genes implicated by our studies, TNK2 and TNR, were each more 
than 1000 amino acids in length, raising potential concern that they would be discovered to 
harbor rare damaging variation by chance because of their large size. However, using 
simulated data sets generated from ExAC allele frequencies, we determined that it was 
statistically unlikely to identify 1 gene (P = .02 to P = .03) or 2 genes (P < .001) using our 
filtering pipeline by chance. The sizes of genes identified in simulations ranged from 463 to 
3144 amino acids, and many genes with modest size were also captured. Families are not 
included in ExAC data, so our simulations were by nature more conservative. In addition, 
although our discovery sample yielded 150 000 SNVs, we also simulated data sets using 250 
000 randomly chosen SNVs for a more conservative estimate of statistical likelihood. 
Therefore, we conclude that TNK2 and TNR are unlikely to be chance findings but rather 
are due to enrichment of rare functional variants associated with PD. Nevertheless, it will be 
important for these genes to be examined in additional replication samples to definitively 
establish their potential contributions to PD risk.
Exome sequencing by design misses possibly important variation in intronic and regulatory 
regions. The use of the GO filter to focus on pathways of interest might have excluded 
important genes that were poorly annotated or were in pathways thus far not associated with 
PD. The GO filter (Figure 1) narrowed the number of variants under consideration from 
6635 to 228 SNVs, ultimately prioritizing 13 SNVs (3 genes) for further study. Had the GO 
filter not been applied, the 6635 SNVs would have been narrowed only to 300 SNVs (87 
genes) using the across-families filter. Future studies with larger sample sizes could use 
formal gene set enrichment analysis to bypass the potential limitation of relying on 
prespecified pathways for variant filtering.
 Conclusions
We used a 2-stage strategy to identify and replicate genes that may harbor rare variants 
contributing to PD susceptibility. Both the discovery and replication samples were composed 
of individuals with familial PD, who may be more likely to segregate rare variants of larger 
effect on disease risk. The 2 genes nominated in this study (TNK2 and TNR) warrant further 
evaluation for their potential role in the pathogenesis of PD.
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Figure 1. Study Design and Discovery Cohort Variant Filtering
Shown is the overall design for the 2-stage study and variant counts at each stage of filtering. 
GO indicates Gene Ontology (annotations listed in the Filtering subsection of the Methods 
section); Indels, insertions or deletions; MAF, minor allele frequency; and SNVs, single-
nucleotide variants.
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Figure 2. Pedigrees Segregating TNK2 and TNR Variants
PD indicates Parkinson disease. A square indicates a male individual; a circle, a female 
individual. Below each symbol is a subject number. For sequenced, affected individuals, the 
age at disease onset is below the subject number. A question mark indicates an unknown age 
at onset.
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Table 1
Clinical Characteristics of Individuals With Parkinson Disease in the Discovery and Replication Cohorts
Clinical Characteristic
Discovery
Cohort
(n = 93)
Replication
Cohort
(n = 49)
No. of families 32 49
Female sex, No. (%) 46 (49.5) 16 (32.6)
Male sex, No. (%) 47 (50.5) 33 (67.3)
Age at onset, mean (SD), y 61.8 (10.0)a 50.1 (15.7)b
Race/ethnicity
  Non-Hispanic European American 90 37
  Hispanic descent … 8
  Non-Hispanic Asian 3 3
  Middle Eastern descent … 1
Ellipses indicate not reported.
a
Data not available for 2 of 93 individuals.
b
Data not available for 6 of 49 individuals.
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